Industry: Drug Manufacturing, Pharmaceuticals, Biotechnology
ThromboGenics is a biopharmaceutical company focused on the development of therapeutics for conditions related to the vascular system. The Company has used its in house expertise to build a significant pipeline of promising drug candidates, a number of which are in clinical trials. The Company is focused on developing new medicines to treat visual disorders, cardiovascular diseases, and cancer, conditions which result from abnormalities to the vascular system. ThromboGenics’ lead product is microplasmin, a stable proteolytic enzyme which is in Phase II trials for eye disease and thrombotic disease. The Company plans to show proof-of-concept for its products by taking them through to completion of Phase II clinical ( www.thrombogenics.com )
ThromboGenics Ltd.
500 7Th Avenue 10Th Floor B
New York, New York 10018
USA
Tel: (212) 201-0920
Fax: (212) 201-0921